OpenNashEarnings

Life Sciences · NYSE: IQV

IQVIA earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

IQVIA's strongest clinical bookings since 2022, driven by full-service wins and AI-enabled bids, came as it deployed 415 AI agents and raised its full-year outlook.

IQVIA saw demand improve across both businesses. Clinical customers awarded more full-service work, including large pharma and emerging biopharma, and win rates rose by two to three points. In commercial, pipelines are at record levels and new drug launches are up. The company says AI is helping it win business: it has deployed 415 agents, launched IQVIA Explorer, and shortened one large trial program by nine months.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$4.4B+8.0% y/yQ3 2026
Q4 2024: $4.0B (worked out from the annual figure)Q4 ’24$4.0BQ1 2025: $3.8BQ1 ’25$3.8BQ2 2025: $4.0BQ2 ’25$4.0BQ3 2025: $4.1BQ3 ’25$4.1BQ4 2025: $4.4B (worked out from the annual figure)Q4 ’25$4.4BQ1 2026: $4.2BQ1 ’26$4.2BQ2 2026: $4.4BQ2 ’26$4.4BQ3 2026: $4.4BQ3 ’26$4.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$4.0B *
Q1 2025$3.8B
Q2 2025$4.0B
Q3 2025$4.1B
Q4 2025$4.4B *
Q1 2026$4.2B
Q2 2026$4.4B
Q3 2026$4.4B
Diluted EPS (GAAP)$2.10+8.8% y/yQ3 2026
Q1 2025: $1.40Q1 ’25$1.40Q2 2025: $1.54Q2 ’25$1.54Q3 2025: $1.93Q3 ’25$1.93Q1 2026: $1.61Q1 ’26$1.61Q2 2026: $1.53Q2 ’26$1.53Q3 2026: $2.10Q3 ’26$2.10
Data
Q1 2025$1.40
Q2 2025$1.54
Q3 2025$1.93
Q1 2026$1.61
Q2 2026$1.53
Q3 2026$2.10

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin12.9%−0.6 pts y/yQ3 2026
Q4 2024: 15.8%Q4 ’2415.8%Q1 2025: 13.0%Q1 ’2513.0%Q2 2025: 12.6%Q2 ’2512.6%Q3 2025: 13.5%Q3 ’2513.5%Q4 2025: 14.4%Q4 ’2514.4%Q1 2026: 12.4%Q1 ’2612.4%Q2 2026: 11.6%Q2 ’2611.6%Q3 2026: 12.9%Q3 ’2612.9%
Data
Q4 202415.8%
Q1 202513.0%
Q2 202512.6%
Q3 202513.5%
Q4 202514.4%
Q1 202612.4%
Q2 202611.6%
Q3 202612.9%
Free cash flow$667.0M−13.6% y/yQ3 2026
Q4 2024: $721.0MQ4 ’24$721.0MQ1 2025: $426.0MQ1 ’25$426.0MQ2 2025: $292.0MQ2 ’25$292.0MQ3 2025: $772.0MQ3 ’25$772.0MQ4 2025: $561.0MQ4 ’25$561.0MQ1 2026: $491.0MQ1 ’26$491.0MQ2 2026: $360.0MQ2 ’26$360.0MQ3 2026: $667.0MQ3 ’26$667.0M
Data
Q4 2024$721.0M
Q1 2025$426.0M
Q2 2025$292.0M
Q3 2025$772.0M
Q4 2025$561.0M
Q1 2026$491.0M
Q2 2026$360.0M
Q3 2026$667.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$4.0Bd$3.8B$4.0B$4.1B$4.4Bd$4.2B$4.4B$4.4B
Operating income$626.0Md$496.0M$506.0M$553.0M$627.0Md$514.0M$506.0M$572.0M
Operating margin15.8%13.0%12.6%13.5%14.4%12.4%11.6%12.9%
Net income$437.0Md$249.0M$266.0M$331.0M$514.0Md$274.0M$256.0M$350.0M
Diluted EPS—$1.40$1.54$1.93—$1.61$1.53$2.10
Operating cash flow$885.0Md$568.0M$443.0Md$908.0Md$735.0Md$618.0M$558.0Md$825.0Md
Capital expenditure$164.0Md$142.0M$151.0Md$136.0Md$174.0Md$127.0M$198.0Md$158.0Md
Free cash flow$721.0M$426.0M$292.0M$772.0M$561.0M$491.0M$360.0M$667.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings